Background. In health technology assessments (HTAs) of interventions that affect survival, it is essential to accurately estimate the survival benefit associated with the new treatment. Generally, trial data must be extrapolated, and many models are available for this purpose. The choice of extrapolation model is critical because different models can lead to very different cost-effectiveness results. A failure to systematically justify the chosen model creates the possibility of bias and inconsistency between HTAs. Objective. To demonstrate the limitations and inconsistencies associated with the survival analysis component of HTAs and to propose a process guide that will help exclude these from future analyses. Methods. We reviewed the survival analysis component of 45 HTAs undertaken for the National Institute for Health and Clinical Excellence (NICE) in the cancer disease area. We drew upon our findings to identify common limitations and to develop a process guide. Results. The chosen survival models were not systematically justified in any of the HTAs reviewed. The range of models considered was usually insufficient, and the rationale for the chosen model was universally limited: In particular, the plausibility of the extrapolated portion of fitted survival curves was very rarely explicitly considered. Limitations. We do not seek to describe and review all methods available for performing survival analysis-several approaches exist that are not mentioned in this article. Instead we seek to analyze methods commonly used in HTAs and limitations associated with their application. Conclusions. Survival analysis has not been conducted systematically in HTAs. A systematic approach such as the one proposed here is required to reduce the possibility of bias in cost-effectiveness results and inconsistency between technology assessments.
Background. In health technology assessments (HTAs) of interventions that affect survival, it is essential to accurately estimate the survival benefit associated with the new treatment. Generally, trial data must be extrapolated, and many models are available for this purpose. The choice of extrapolation model is critical because different models can lead to very different cost-effectiveness results. A failure to systematically justify the chosen model creates the possibility of bias and inconsistency between HTAs. Objective. To demonstrate the limitations and inconsistencies associated with the survival analysis component of HTAs and to propose a process guide that will help exclude these from future analyses. Methods. We reviewed the survival analysis component of 45 HTAs undertaken for the National Institute for Health and Clinical Excellence (NICE) in the cancer disease area. We drew upon our findings to identify common limitations and to develop a process guide. Results. The chosen survival models were not systematically justified in any of the HTAs reviewed. The range of models considered was usually insufficient, and the rationale for the chosen model was universally limited: In particular, the plausibility of the extrapolated portion of fitted survival curves was very rarely explicitly considered. Limitations. We do not seek to describe and review all methods available for performing survival analysis-several approaches exist that are not mentioned in this article. Instead we seek to analyze methods commonly used in HTAs and limitations associated with their application. Conclusions. Survival analysis has not been conducted systematically in HTAs. A systematic approach such as the one proposed here is required to reduce the possibility of bias in cost-effectiveness results and inconsistency between technology assessments. Key words: oncology; cost-utility analysis; technology assessment; pharmacoeconomics; modeling; survival analysis; overall survival; resource allocation (Med Decis Making 2013; 33:743-754) I nterventions that affect survival or any other timeto-event outcome form a high proportion of the treatments appraised by health technology assessment (HTA) agencies. In these it is essential to accurately estimate the survival benefit associated with the new intervention in order to obtain a credible and reliable estimate of the incremental cost-effectiveness ratio (ICER) for each competing decision alternative. This is made difficult because clinical trial-based survival data are often censored, which means that the end point of interest is not observed for all individuals. Censoring is usually attributable to administrative reasons (some individuals may not experience the event before the end of the trial follow-up period) or because an individual has been lost to follow-up. 1 Censored data are different from missing data because the former are partially known (we know that an individual is alive up to a certain time point) but in the presence of censoring it is not possible to estimate mean survival times based on trial data alone.
Because economic evaluations attempt to reflect all differences in costs and outcomes between competing decision alternatives in order to help inform resource allocation decisions, a lifetime horizon is usually advocated, particularly for interventions that affect survival. [2] [3] [4] [5] Therefore, in the presence of censoring, extrapolation is required to predict the complete survival impact of the new intervention, which may be summarized as the mean survival benefit.
Extrapolation is fraught with difficulties, which are discussed in this article. Given these issues, commentators have suggested that analyses could instead be based on differences in survival probabilities at a designated time point. [6] [7] [8] However, this excludes quality of life from the analysis, and selected time horizons may be regarded as arbitrary and unhelpful for resource allocation decisions.
Extrapolation can be performed using a number of different techniques. Generally parametric models are used, but there are a variety of these and they can be fitted in different ways. The choice of model can have a substantial impact on survival estimates because they have different functional forms. In turn, this can significantly alter cost-effectiveness estimates and may influence recommendations made by decision makers. For example, in the 2009 National Institute for Health and Clinical Excellence (NICE) appraisal of rituximab for leukemia, the use of a Gompertz distribution rather than a Weibull distribution for modeling progression-free survival (PFS) increased the ICER from approximately £13,000 to £23,000. 9 NICE typically recommends treatments that have an ICER below £20,000-£30,000 per quality-adjusted life year gained, and thus in this case the choice of survival model may have altered the decision made. 2 The impact of alternative survival models had a larger absolute impact on the ICER in the 2009 renal cell carcinoma NICE appraisal, where it was demonstrated that the use of a log-logistic model rather than a Gompertz model reduced the ICER from £75,000 to £40,000, 10 but in this case the ICER did not cross the cost-effectiveness threshold.
Different extrapolation methods are likely to be appropriate in different circumstances, and the use of different models in different HTAs is not necessarily a problem. However, if the chosen approach is not adequately justified there is a possibility that the most appropriate model is not selected, which gives rise to the potential for inconsistent and biased analyses, which may lead to erroneous cost-effectiveness analysis (CEA) results.
The purpose of this article is to draw on weaknesses identified in completed HTAs and recently published research to develop a process guide to improve the quality of the survival analyses included within future economic evaluations. Adoption of such a guide would help analysts avoid common pitfalls and reduce bias while also promoting consistency between HTAs. It would also help decision makers to determine how much confidence to place in CEA results. Our focus is specifically on instances in which patient-level data are available from 1 pivotal randomized controlled trial (RCT). Evidence synthesis is not considered in detail-clearly this represents an area for further research. In this article we do not describe the different parametric distributions and statistical tests in detail, as information on these is available elsewhere. 1 Instead we focus on their empirical use in an economic evaluation context. In the first section of this article, we provide background to place our research in context; a conceptual review of recent articles investigating the extrapolation of survival data in a CEA setting is presented. In the next section, we describe a review of survival modeling methods commonly used in CEAs and of techniques commonly used to select and justify chosen methods. This review provides examples of suboptimal practice. Next our model selection process algorithm is presented, which is designed to avoid the suboptimal practice observed in the preceding review of survival modeling methods and which also draws upon the previous research reported in the Background section. Given the process by which our algorithm is developed, it does not represent the only such algorithm that may be constructed and we would expect it to evolve with further research. In the last section we discuss our findings and the limitations associated with our research, highlight areas that are particularly important for further research, and make concluding remarks.
BACKGROUND
Several major issues are faced by analysts attempting to extrapolate RCT data for use in CEA. In their summary of methodological issues that arise in the economic analysis of cancer treatments, Tappenden and others 11 noted the requirement for extrapolation and concluded that further research was needed to explore the validity of the numerous available extrapolation methods. They did not discuss alternative methods in detail but mentioned that often analysts fit exponential, Weibull, or Gompertz parametric models to estimate control group survival and then apply a hazard ratio (HR) to derive the survival curve for the experimental group. This requires an assumption of proportional hazards (PH)-that is, the HR is constant over time-and in this article we refer to this as PH modeling. Recently several articles have further investigated extrapolation in the context of CEA.
Guyot and others 12 reviewed the survival analysis undertaken alongside 24 CEAs in HTAs undertaken for NICE. They found that most often, PH modeling was undertaken. However, the authors noted 2 important problems with these analyses; first, none of the studies formally tested the PH assumption; second, the source of the HR used within these analyses was not specified-which may cause bias if the HR was derived from an unrelated model. In 2 studies, parametric models were fitted independently to the control and experimental groups-avoiding the PH assumption. The authors found that each of the 1and 2-parameter parametric models-exponential, Weibull, Gompertz, log-normal, and log-logistic-was used to some extent, with the exponential and Weibull being the most common. We refer to these as the ''standard'' parametric models. Key weaknesses of the reviewed analyses were that models were generally chosen based only on their visual fit to the Kaplan Meier curve and no studies compared all of the available standard parametric models. Only 1 study made use of a suitable statistical measure (Akaike's information criterion [AIC]) to compare the statistical fit of alternative models. Given these failings, the authors concluded that an analytical protocol specifying a common process for model selection may be required to improve the quality of future analyses.
Connock and others 13 illustrated issues associated with extrapolation of RCT survival data in a CEA context by drawing on 2 HTAs undertaken for NICE. In the 2 case studies, log-logistic and log-normal parametric models were used to model survival, and these led to survival advantages that were double those produced by Weibull models. The model choices were justified solely using AIC values, but the authors argued that statistical measures of fit to the observed data should not be the only consideration when choosing models. They suggested that in one of the case studies the extrapolation lacked face validity and that the longer-term plausibility of competing models should be tested against external data. The authors also stated that when trials have survival curves with long tails exhibiting few events, the robustness of extrapolations using information from the tails should be tested using sensitivity analysis, because these segments of the curves are highly uncertain.
Davies and others 14 presented a similar review of the use of parametric survival modeling in CEAs, using 1 cancer-related case study. They discussed the use of standard parametric models and the fitting of these under proportional treatment effect assumptions (i.e., a constant HR or acceleration factor over time), or based on independently fitted distributions for each treatment arm, and recognized that if proportional treatment effects are assumed, these should be justified using log-cumulative hazard or quantilequantile plots. The authors discussed fitting survival models to complete trial data compared with selecting a point on the Kaplan-Meier curve from which to extrapolate, and they emphasized that choosing points from which to extrapolate can be arbitrary and problematic, particularly when numbers at risk of the event are small. The authors suggested that where standard parametric models do not appear suitable for representing the hazards observed, flexible parametric survival functions may be used-however, further details on these were not given.
Recently, researchers have developed more complex methods for carrying out survival modeling in the context of CEA. Ouwens and others 15 and Jansen 16 describe methods for conducting PH modeling allowing for a treatment effect with more than 1 dimension (which relaxes the PH assumption). Demeris and colleagues 17 have demonstrated the use of a poly-Weibull model, a flexible parametric model that-unlike a standard Weibull model-can be used to represent nonmonotonic hazards. Demeris and Sharples 18 have also shown how external data sources such as patient registries and population statistics might be used to inform extrapolation within an Bayesian evidence synthesis framework. Jackson and Sharples 19 demonstrate the use of 3-and 4parameter survival models (generalized gamma and generalized F models, respectively) in a CEA setting, as well as Bayesian semiparametric survival models with piecewise-constant hazard functions. The authors apply flexible parametric methods in the context of extrapolation, whereas spline-based flexible parametric models were initially introduced as methods for modeling complex hazard and survival functions, rather than as extrapolation methods. 20 Previous research has demonstrated key issues associated with the extrapolation of survival data in a CEA context, but none has drawn together ''accepted'' knowledge to provide an analysis protocol similar to that described by Guyot and others. 12 Authors agree that chosen survival models should not be justified based only on statistical measures (internal validity) and that clinical plausibility (external validity) is important. There appears to be consensus that all ''standard'' parametric models (exponential, Weibull, Gompertz, log-normal, loglogistic) should be considered, and sometimes more flexible models may be required. There is a clear need for further research-in particular investigating the use of external data and knowledge to ensure external validity-but in the interim it is useful to provide an analysis protocol based on current knowledge. Next we present our own review of extrapolation and model selection justification methods used in CEAs, after which we draw on this and previous research to develop our model selection process algorithm.
NOVEL REVIEW

Methods
We reviewed all NICE technology appraisals (TAs) that dealt with advanced and/or metastatic cancer and had been completed by December 2009. We chose these TAs because survival parameters were highly likely to be key within the economic model. All appraisal documents available on the NICE Web site (www.nice.org.uk) were reviewed to determine the survival analysis method used within the CEA component of the appraisal. These included submissions made by manufacturers as well as reports developed by independent academic groups that review these submissions and present novel analyses on behalf of NICE.
The methods for estimating survival inputs for the economic model were identified, and the techniques used to justify the chosen methods were examined. We focused on 3 areas when reviewing the survival analyses. These are in line with the key issues noted in the articles reviewed earlier:
Concentrating on these 3 areas allowed us to identify common methodological weaknesses and limitations associated with which models are used, how models are applied, and how models are justified. It is not possible to cover every issue highlighted by each TA in this article; instead, we focus on highlighting key analytical weaknesses with a small number of examples. Because we reviewed both manufacturer submissions and independent academic group reports, our review is relevant both for how survival modeling should be undertaken and for how survival modeling completed by someone else should be reviewed.
Results and Review
Forty-five TAs were identified and included in the review. These are listed as supplementary material in Table S1 .
Modeling Methods. Five broad approaches for estimating mean survival (or the entire survival distribution) were identified (see Table 1 ): 1) restricted means analysis, 2) parametric modeling, 3) PH modeling, 4) external data modeling, and 5) other ''hybrid'' methods. In 17 (38%) TAs, extrapolation was not performed, with the survival analysis based purely on the observed trial data (restricted means analysis). Appropriately, this was generally only the case when there was relatively little censoring in the survival data from the trial. It is important to note that survival data may appear to be relatively complete even in the presence of substantial censoring: If the last observed data point represents an event rather than a censored observation, the Kaplan Meier curve will fall to zero. A restricted means approach may be taken in these circumstances, but where numbers at risk at the tail of the survival curve are very low, using a parametric survival model to extrapolate the data may be more appropriate.
Parametric modeling. Thirty-two of the 45 TAs reviewed (71%) used parametric extrapolation techniques in order to produce estimates of survival. The most popular parametric models were the Weibull and exponential; the Weibull was used in 23 TAs (72% of those that involved extrapolation) and the exponential in 20 (63% of those that involved extrapolation). Other models (such as the Gompertz, log-normal, log-logistic, and generalized gamma) were used considerably less often (see Table 1 ).
The methods used to fit the parametric models varied. Usually the manufacturer had access to patientlevel data and thus could fit parametric models using these, whereas the independent academic groups that review the manufacturer analyses typically had to use a computer digitization program to reproduce published Kaplan Meier curves so that parametric models could be fitted. This data availability issue has been important in the past but in the future it is likely to be less so, because of novel research that allows patient-level data to be accurately replicated from a published Kaplan Meier curve. 21 It was most common for all survival data points to be used when fitting parametric models to trial data. However, in some TAs, models were fitted using a restricted data set. For example, in TA86 (imatinib for gastrointestinal stromal tumors) and TA121 (carmustine implants and temozolomide for glioma), the manufacturer and the independent academic group fitted exponential parametric models using trial data only up to certain specified time points. 22, 23 The final observed survival events were excluded from the model-fitting process because these were argued to be highly uncertain because of a high level of censoring. The robustness of this is highly questionable because excluding data points means that the level of uncertainty is increased further. Data should only be excluded if it can clearly be shown that implausible outliers exist, based on external data or clinical expert opinion.
A variation on the approach of restricting the data to a certain time point when fitting parametric models was used in TA169 (sunitinib for renal cell carcinoma) and TA179 (sunitinib for gastrointestinal stromal tumors). 24, 25 In both cases, the manufacturers fitted Weibull models to the survival data using only 1 data point per month. This was perceived to allow the fitted models to follow the Kaplan Meier curve more closely from a visual perspective. However, this implicitly places greater than proportionate weight on segments of the Kaplan Meier where there are fewer data points and does not place proportionate weight on areas where a large number of data points are observed. Furthermore, this requires single data points to be chosen for inclusion in the analysis; the choice of the included points is likely to be arbitrary, whereas excluding other data points leads to greater uncertainty. This is therefore a potentially biased technique and is directly at odds with the method of excluding data from the right-hand side of the Kaplan Meier curve from the analysis: The latter places no weight on the events observed at the right-hand side of the Kaplan Meier, whereas the former implicitly places a high weight on these events. Both methods are likely to bias the resulting survival estimates and should be avoided.
Proportional hazards modeling. Some use of PH modeling was evident in 19 (59%) of the 32 TAs that involved extrapolation of survival data. In some instances, PH modeling was tested as a structural uncertainty sensitivity analysis (with independent model fitting for each treatment group-avoiding assumptions of proportionalityforming the base case), whereas in other TAs it was the only method for extrapolation used.
PH modeling was most often used when multiple comparators were included in the evaluation and where patient-level data were not available for all comparators, for example, TA70 (imatinib for leukemia), TA91 (paclitaxel, pegylated liposomal doxorubicin hydrochloride, and topotecan for ovarian cancer), and TA93 (irinotecan, oxaliplatin, and raltitrexed for colorectal cancer). [26] [27] [28] However, there was also some use of PH modeling when single comparators were included in the economic model and when patient-level data from the pivotal RCT were available, for example, TA137 (rituximab for lymphoma) and TA174 (rituximab for leukemia). 29, 30 Of the TAs that used PH modeling, few made explicit assumptions about the duration of treatment effect. This implies that the HR observed in the trial lasts for the entire duration of the economic modeltypically a lifetime. This may be clinically implausible. Alternatively one could assume that the treatment effect is maintained until the end of the trial follow-up reflecting the available evidence (e.g., TA65 31 ) or could select a cutoff point related to disease progression or time (e.g., TA70 26 ). Both of these options are arbitrary in nature and require explicit justification. Within these TAs, such justification was not evident.
External data. Within 4 TAs, external registry data were used to inform the extrapolation of survival estimates, given a lack of long-term survival data within the relevant trials. This typically involved applying death rates from external data to the posttrial time period. Usually it was assumed that the risk of death in this period was the same whether PH modeling was used or the patient was initially randomized to the intervention or the control treatment. The former approach was taken in TA110 (rituximab for follicular lymphoma). 32 This implies an overall survival (OS) benefit correlated with the PFS gain. Within the rituximab appraisal, the validity of this surrogate relationship had not been proven, so the independent academic group conducted sensitivity analysis assuming that none of the PFS gain translated to OS. 32 In TA129 (bortezomib for multiple myeloma) a variation of PH modeling was used, whereby external data were used to estimate long-term survival for the control group and an HR was applied to estimate survival in the experimental group, It was assumed that the HR declined over time but that some effect was maintained for 3 years. 33 The independent academic group highlighted this as a key weakness of the manufacturer's analysis because the assumptions concerning the duration and decline of the treatment effect were not justified. 34 Other hybrid methods. Most TAs implemented standard methods when fitting models to estimate mean survival. However, some novel approaches were used, most notably by the independent academic group who reviewed the manufacturer's analyses in TA181 (pemetrexed for lung cancer), whose analysis bore similarities to a method previously suggested by Gelber and others. 35 The independent academic group stated that the exponential and Weibull models used by the manufacturer provided poorly fitting survival curves, and to investigate this further they examined the cumulative hazard function and noted that standard parametric models were not compatible with the trial data, attributable to hazard rates and ratios that changed over time. 36 However, they also observed that for each group at some point following the end of treatment, the cumulative hazard function assumed a steady linear increase that was indicative of a constant risk of death per unit of time. Consequently, the independent academic group elected to model survival using the observed Kaplan Meier curve itself for shortterm survival and supplemented this with an exponential model for long-term survival. Although this is unlikely to be suitable in all circumstances (often the long-term survival prognosis will not be accurately represented by an exponential distribution), it demonstrates the value of closely examining the hazard rates observed in the trial.
Model Selection and Justification. The techniques used to justify chosen survival modeling methods are summarized in Table 2 . In 22 (69%) of the 32 TAs that used a parametric model-based extrapolation technique, some justification for the extrapolation technique was provided. However, the justification given was often very brief and none of the TAs provided a complete justification including a detailed assessment of the fit of all standard parametric models to the trial data combined with a robust assessment of the plausibility of the extrapolated portion of the models. Importantly, only 17 (38%) of the TAs tested the fit of more than 1 parametric model-representing a clear limitation of the analyses.
Visual inspection. Visual inspection provided the only justification for the chosen parametric model in a number of TAs. Often if the parametric model was seen to follow the Kaplan Meier curve reasonably closely, it was accepted as a good fit and no further justification was given. In many instances, the visual inspection would consist only of assessing the fit of 1 parametric model. However, on a number of occasions 1 model was classified as a better fit than others based only on visual inspection.
Statistical tests. A range of statistical tests, plots, and analyses were used to justify parametric model choices in the different TAs; however, these were not used systematically. AIC and the Bayesian information criterion (BIC) provide useful measures of the relative fit of alternative parametric models to the observed data, and these statistics were presented relatively regularly, whereas plots of residuals were only occasionally presented. Log-cumulative hazard plots were underused given their value in determining which parametric models are compatible with the observed hazards and their usefulness in determining the suitability of the PH assumption, which is essential when PH modeling is used. Quantilequantile plots (as described by Bradburn and others 37 ), which can be used to assess the suitability of Accelerated Failure Time models (such as lognormal and log-logistic models), were not used in any of the TAs included in the review.
Clinical validity and external data. Assessment of the appropriateness of the extrapolated portion of the survival curve was very rare. In TA135 (pemetrexed for mesothelioma) external data were used to determine the appropriateness of alternative parametric models, but this was an isolated instance. The independent academic group used Surveillance, Epidemiology and End Results (SEER) cancer statistics on long-term survival to demonstrate that a Weibull model extrapolated more appropriately than an exponential. 38 Systematic assessment. None of the reviewed TAs included full and systematic justification of the chosen parametric models. In some TAs, multiple justifications were used, but in all cases flaws remained. For example, in TA135 (pemetrexed for mesothelioma) the choice of parametric model was based on an analysis of the observed hazard together with a consideration of expected long-term survival based on external data; however, the exploratory analysis of the hazard was not described and only a limited range of parametric models were considered 38 -thus other more suitable models may potentially have been overlooked. In the manufacturer's submission for TA137 (rituximab for lymphoma) consideration was given to a range of parametric models, AIC and BIC were measured, and the validity of the extrapolated tails of the survival curves was also considered. 29 However, log-cumulative hazard plots were not presented even though PH modeling was used, and no data or other justifications were used to support assumptions made about the clinical validity of long-term survival estimates.
MODEL SELECTION PROCESS ALGORITHM
In this section we introduce our model selection process algorithm, based on the review of extrapolation techniques used within NICE HTAs presented earlier and upon the previous research summarized at the beginning of the article. The model selection process algorithm is presented in Figure 1 . Three key underlying principles influence the process described:
The analyst should demonstrate that all ''standard'' parametric models (exponential, Weibull, Gompertz, log-logistic, log-normal) have been considered and compared in order to make evident that the model choice has not been arbitrary. If standard models appear unsuitable, the use of more flexible parametric models (such as the generalized gamma and generalized F models), piecewise modeling, and other novel survival modeling methods such as those demonstrated by Royston and Parmar 20 and Jackson and others 19 should be considered. The fit of alternative models should be assessed systematically, including consideration of the fit to the observed data (internal validity) and the plausibility The model selection process algorithm presents a step-by-step process through which appropriate survival models can be identified. First, models that are appropriate for modeling the observed data are identified based on an analysis of the hazards. This includes a consideration of the PH assumption. Appropriate models are then compared based on their statistical fit to the observed data, and models that provide a plausible extrapolation are identified by drawing on external data and clinical expert opinion. The duration of the treatment effect should be explicitly considered at this stage. In the model selection decision, the weight given to the comparative fit of alternative models to the observed data depends on the extent to which extrapolation is required and the degree of censoring present. If very little extrapolation is required and there is little censoring, the fit to the observed data is of most importance. However, if substantial extrapolation is required, the plausibility of the extrapolated portion of alternative models is of greater importance than the fit to the observed data. Finally, the most suitable model should be chosen, but alternative plausible models (based upon internal and external plausibility) should be considered in sensitivity analysis.
DISCUSSION
In NICE HTAs, exponential and Weibull models have been used most often to conduct extrapolation. More flexible models such as the generalized gamma and piecewise models have been used very rarely, and complex models such as those described by Royston and Parmar 20 and Jackson and others 19 have not been used in practice. This is a concern, as more flexible models are more likely to be compatible with the hazard rates observed in clinical trials-particularly when these vary significantly over time. In addition, a further problem is that analysts take inconsistent approaches to fitting models-with data sometimes excluded arbitrarily in order to achieve a ''better'' fit. Excluding data increases uncertainty, and if any data points do appear to be outliers suitable for exclusion, this must be rationalized very clearly. These are important issues highlighted by our review and previous reviews, [12] [13] [14] but of greater concern is that the method chosen to extrapolate survival data was not systematically justified in any of the reviewed NICE CEAs, and often only a very limited subset of parametric models were considered.
Given the important effect that the application of different parametric models can have on cost-effectiveness estimates, it is not sufficient to fit 1 survival model and to justify its fit solely on the basis of visual inspection. However, this practice is common-only 38% of TAs considered more than 1 parametric model, and visual inspection was the most commonly used justification method. One particular model may appear to fit the observed data reasonably well, but that does not mean that other models should not be considered: They may fit the data similarly well but may produce significantly different survival estimates due to differences in their functional forms leading to divergences in their extrapolated portions. Although it may be reasonable to exclude a model if it appears to fit the data very poorly based on a visual inspection, such analysis is subjective and arbitrary when comparing models with similar fits and takes no account of the plausibility of the extrapolated portion of the curves.
Statistical measures such as AIC and BIC and plots of hazards and residuals are more accurate methods of assessing the fit of alternative models. The use of such measures has been recommended in previous research, [12] [13] [14] but these too are only useful for determining the fit of the models to the observed datathey tell us nothing about the plausibility of the extrapolations. When there is little censoring, greater emphasis can be placed on statistical tests and plots, but when this is not the case it is of great importance to justify the plausibility of the extrapolated portion of the survival model chosen, as this is likely to have a very large impact on mean survival estimates. This is difficult but may be achieved through the use of external data sources (from other trials or registries), an examination of biological plausibility (is the treatment effect likely to be maintained?), or clinical expert opinion alongside a consideration of the hazard functions of the alternative parametric models. There are obvious limitations to the use of external sources of information (e.g., compatibility with the trial in question and lack of evidence), but despite this, making some attempt to justify the extrapolated portions of curves is preferable to no justification.
In the NICE context, it is common for manufacturers to be asked to undertake further analysis of survival data. This could be avoided if manufacturers conducted their survival analysis systematically from the outset. Following the model selection process that we recommend promotes this and should improve the likelihood that appropriate survival models are chosen, leading to more robust economic evaluations. This would also promote process transparency and consistency between HTAs.
Although our model selection process algorithm improves the likelihood that survival analysis will be conducted more systematically and appropriately, it should not be viewed as a finished product. There are several very important areas in which further research is required, and as such the suggested model selection process algorithm should evolve over time.
In particular, methods for modeling survival that are more complex than the standard parametric models are not currently well understood and are seldom used. As suggested by Guyot and others, 12 experiments with different curve-fitting methods, and perhaps simulation studies, would be beneficial to assess the effects of model choice. It is because of this current lack of understanding that we have been unable to be more prescriptive in our recommendations for the application of specific models in base case and sensitivity analyses. Also, although we have suggested the use of external data to demonstrate the external plausibility of fitted models, we have not discussed in detail ways in which this could be done. Demeris and Sharples 18 have made suggestions, but considering the importance of external validity in justifying model choice, substantially more research in this area is essential.
Limitations
We have focused primarily on undertaking survival analysis in the context of an economic evaluation alongside a clinical trial in which patient-level data are available and evidence synthesis is not required. Methods used are dictated by the data available and the comparisons required within an HTA: Several of the HTAs reviewed here required comparisons to treatments that were not included in the pivotal trial of the novel intervention, and therefore evidence synthesis was required and patient-level data for all relevant trials were not available. Guidance on the use of survival analysis methods when evidence synthesis is required is beyond the scope of this article, but even when this is the case, some analysis of trial data is common (e.g., to estimate a baseline survival curve or to estimate a hazard ratio), and as such the suitability of fitted models should be assessed. Recently methods have emerged that allow close approximations of patient-level data to be derived from published Kaplan Meier curves 21 -once these data have been derived, the process guide we present here becomes applicable.
Importantly, the emphasis of this article is on the process for undertaking survival analysis based on a review of what is commonly done in practice. We do not seek to exhaustively specify all potentially relevant methods or to describe in detail the particular characteristics of the models mentioned here. All the methods discussed in this article are standard methods documented in many statistics textbooks, and details on their functional forms and key characteristics are available elsewhere (for example, see Collett 1 ). We acknowledge that other more complex and novel methods are also available, and although a selection of these are mentioned we have not been exhaustive.
CONCLUSION
It is essential that survival analysis be conducted in a systematic way in health technology assessment. Otherwise it cannot be demonstrated that the most appropriate survival model has been chosen. Justification should be based on the fit of alternative models to the observed data and the clinical plausibility of the extrapolated portion of the curve. Currently, survival analysis is not conducted in a systematic way in HTA, which means inappropriate methods may have been used. Using the process guide suggested here will reduce the likelihood of this, will promote consistency, and will allow decision makers to be more confident in the economic analyses presented to them.
ACKNOWLEDGMENTS
This article is an abridged version of the NICE Decision Support Unit (DSU) Technical Support Document (TSD) on survival analysis. 39 The DSU thanks Tony Ades, Peter Clark, Neil Hawkins, Peter Jones, Steve Palmer, and the team at NICE, led by Gabriel Rogers, for reviewing this document. Thanks also to Paul Tappenden for his comments on various drafts of this article.
